Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs

American Journal of Cancer Research

Volumn 6, Issue 11, 2016, Pages 2514-2531

  Du Four, Stephanie ^a   Maenhout, Sarah K ^a   Niclou, Simone P ^c   Thielemans, Kris ^a,b   Neyns, Bart ^b   Aerts, Joeri L ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

Antiangiogenesis; CTLA 4 blockade; DCs; MDSC; Melanoma brain metastases; Tumor microenvironment

Indexed keywords

AXITINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MALE; MELANOMA; MONOCYTE; MONOTHERAPY; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; SPLEEN CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 85007247156     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bafaloukos D and Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev 2004; 30: 515-520.
2. Chapman PB, Hauschild A, Robert C, Haanen J, Ascierto PA, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman J, Kirkpatrick JP, Eggermont A, Dreno B, Nolop K, Nelson B, Hou J, Lee RJ, Flaherty KT and McArthur GA. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 364: 2507-2516.
3. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V and Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. The Lancet 2012; 380: 358-365.
4. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D and Group MS. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-114.
5. Hodi FS, O'Day SJ, McDermott D, Weber RW, Sosman JA, Haanen J, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchock JD, Weber J, Tian J, Yellin MJ, Nichol GM, Hoos A and Urba WJ. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 2010; 363: 711-723.
6. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V and Ascierto PA. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.
7. Robert C, Thomas L, Bondarenko I, O'Day SJ, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A and Wolchock JD. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med 364: 2617-2626.
8. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin A-M, Guckert M, Goodman V, Streit M, Kirkwood JM and Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 1087-1095.
9. Dummer R, Goldinger SM, Turtschi CP, Egg-Mann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L and Rinderknecht JD. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014; 50: 611-621.
10. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN and Hodi FS. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13: 459-465.
11. Huang Y, Yuan J, Righi E, Kamoun WS, Ancu-Kiewicz M, Nezivar J, Stantosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang PH, Duda DG, Fukumura D, Jain RK and Poznansky MC. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012; 109: 17561-17566.
12. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S and Carbone DP. Vascular Endothelial Growth Factor Inhibits the Develop-ment of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hema-topoietic Lineages In Vivo. Blood 1998; 92: 4150-4166.
13. Gabrilovich DI, Ostrand-Rosenberg S and Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-268.
14. Jain RK. Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell 2014; 26: 605-622.
15. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP and Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70: 6171-6180.
16. Du Four S, Maenhout SK, Depierre K, Renmans D, Niclou SP, Thielemans K, Neyns B and Aerts JL. Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. Oncoimmunology 2015; 4: e998107.
17. Meyer C, Cagnon L, Costa-Nunes CM, Baum-Gaertner P, Montandon N, Leyvraz L, Michielin O, Romano E and Speiser DE. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2014; 63: 247-257.
18. Pico de Coana Y, Poschke I, Gentilcore G, Mao Y, Nystrom M, Hansson J, Masucci GV and Kiessling R. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res 2013; 1: 158-162.
19. Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, Rao UN and Kirkwood JM. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 2014; 9: e87705.
20. Goyvaerts C, De Groeve K, Dingemans J, Van Lint S, Robays L, Heirman C, Reiser J, Zhang XY, Thielemans K, De Baetselier P, Raes G and Breckpot K. Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther 2012; 19: 1133-1140.
21. Keyaerts M, Remory I, Caveliers V, Breckpot K, Bos TJ, Poelaert J, Bossuyt A and Lahoutte T. Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging. PLoS One 2012; 7: e30061.
22. Maenhout SK, Van Lint S, Emeagi PU, Thiele-Mans K and Aerts JL. Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts. Int J Cancer 2014; 134: 1077-1090.
23. Leach D, Krummel MF and Allison JP. En-hancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736.
24. Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A and Wolchok JD. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 2011; 60: 1137-1146.
25. Quezada SA, Peggs KS, Curran MA and Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006; 116: 1935-1945.
26. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small E and Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008; 112: 1175-1183.
27. Gabrilovich D, Ishida T, Nadaf S, Ohm JE and Carbone DP. Antibodies to Vascular Endothelial Growth Factor Enhance the Efficacy of Cancer Immunotherapy by Improving Endogenous Dendritic Cell Function. Clin Cancer Res 1999; 5: 2963-2970.
28. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schimdt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LSK and Sansom DM. Trans-endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4. Science 2011; 332: 600-603.
29. Wang XB, Fan ZZ, Anton D, Vollenhoven AV, Ni ZH, Chen XF and Lefvert AK. CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation. BMC Immunol 2011; 12: 21.
30. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R and Ochoa AC. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69: 1553-1560.
31. Liu Y, Yu Y, Yang S, Zeng B, Zhang Z, Jiao G, Zhang Y, Cai L and Yang R. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother 2009; 58: 687-697.